F

Fennec Pharmaceuticals Inc
NASDAQ:FENC

Watchlist Manager
Fennec Pharmaceuticals Inc
NASDAQ:FENC
Watchlist
Price: 7.49 USD 0.67% Market Closed
Market Cap: 255.8m USD

Fennec Pharmaceuticals Inc
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Fennec Pharmaceuticals Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
F
Fennec Pharmaceuticals Inc
NASDAQ:FENC
Cash from Operating Activities
-$7.5m
CAGR 3-Years
20%
CAGR 5-Years
12%
CAGR 10-Years
-15%
Abbvie Inc
NYSE:ABBV
Cash from Operating Activities
$20.9B
CAGR 3-Years
-3%
CAGR 5-Years
5%
CAGR 10-Years
15%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Operating Activities
$9.7B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Cash from Operating Activities
$13.1B
CAGR 3-Years
10%
CAGR 5-Years
4%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Operating Activities
$3.7B
CAGR 3-Years
-3%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Operating Activities
$5.1B
CAGR 3-Years
-4%
CAGR 5-Years
18%
CAGR 10-Years
15%
No Stocks Found

Fennec Pharmaceuticals Inc
Glance View

Market Cap
255.8m USD
Industry
Biotechnology

Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Durham, North Carolina and currently employs 10 full-time employees. The company went IPO on 2001-06-05. The firm is focused on the development of PEDMARK for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The Company’s only product candidate in the clinical-stage of development is PEDMARK. The company announced two results of Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children, including the pivotal Phase III study SIOPEL 6 and the proof-of-concept Phase III study in collaboration with the Children’s Oncology Group (COG ACCL0431). PEDMARK has the potential to reduce the incidence and/or grade of chemotherapy-induced hearing loss. The Company’s four subsidiaries includes Oxiquant, Inc. and Fennec Pharmaceuticals, Inc., both Delaware corporations, Cadherin Biomedical Inc., a Canadian company, and Fennec Pharmaceuticals (EU) Limited (Fennec Limited), an Ireland company. Apart from Fennec Pharmaceuticals, Inc., all subsidiaries are inactive.

FENC Intrinsic Value
HIDDEN
Show

See Also

What is Fennec Pharmaceuticals Inc's Cash from Operating Activities?
Cash from Operating Activities
-7.5m USD

Based on the financial report for Sep 30, 2025, Fennec Pharmaceuticals Inc's Cash from Operating Activities amounts to -7.5m USD.

What is Fennec Pharmaceuticals Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-15%

The average annual Cash from Operating Activities growth rates for Fennec Pharmaceuticals Inc have been 20% over the past three years , 12% over the past five years , and -15% over the past ten years .

Back to Top